26 August 2025 | 8:44PM HKT Asymchem (6821.HK) Buy 2Q25 earnings review: Full-year revenue guidance raised to 13–15%, peptide capacity expansion underway; Buy | 6821.HK | 12m Price Target: HK$96.60 | Price: HK$91.40 | Upside: 5.7% | | --- | --- | --- | --- | | 002821.SZ | 12m Price Target: Rmb128.50 | Price: Rmb103.30 | Upside: 24.4% | Asymchem reported solid 2Q25 results, broadly in line with GSe and ahead of Visible Alpha consensus (sales/ adj. NP +7%/+6% higher). Revenue reached Rmb1.65bn, +27.5% y/y, su ...